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Abstract CXCR4 is the receptor for the CXC chemokine SDF1
that has essential functions on embryo organogenesis, immuno-
logical functions and T lymphocyte trafficking. Recently,
CXCR4 has drawn unexpected attention as it was recently
identified as a co-factor required for entry of lymphotropic HIV
isolates in CD4+ T lymphocytes. CXCR4 is the only SDF1
receptor identified so far. This suggests that CXCR4 expression
is critical for the biological effects of SDF1. To investigate the
mechanisms controlling both the constitutive and induced
expression of CXCR4 receptors we have isolated and character-
ized the promoter region and determined the genomic structure of
the human gene. The CXCR4 gene contains two exons separated
by an intronic sequence. A 2.6 kb 5P-flanking region located
upstream the CXCR4 open reading frame contains a TATA box
and the transcription start site characteristic of a functional
promoter. This region also contains putative consensus binding
sequences for different transcription factors, some of them
associated with the hemopoiesis and lymphocyte development.
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1. Introduction
Chemokines are soluble mediators that control leukocyte
migration into sites of in£ammation and speci¢c areas of
lymphoid organs [1]. Activation of leukocytes is mediated
by interaction of chemokines with speci¢c receptors belonging
to the family of the seven transmembrane domain, G-protein
coupled receptors [2]. Chemokines carry conserved cysteines
and fall into four families de¢ned by a cysteine signature
motif : CXC, CC, C or CX3C where C is a cysteine and X
any amino-acid residue [3]. Most of the chemokines belong to
either CC or CXC families. Expression of CC chemokine
receptors in T lymphocytes has proved to be dependent on
the cell activation status and the nature of the signal used as
stimulus. Thus, expression of CCR1, CCR2 or CCR5 are
induced by IL2 [4,5], but are down-regulated by lectin or T
cell speci¢c activators [4,6]. Less information is available for
the CXC family of receptors, although it has been reported
that expression of IL8 receptors in lymphocytes is modi¢ed
neither by IL2- nor CD3-mediated activation [4]. Among the
family of CXC receptors, CXCR4 has drawn unexpected at-
tention as it was identi¢ed as a co-factor required for entry of
lymphotropic HIV isolates in CD4+ T lymphocytes [7].
CXCR4 is the receptor for the CXC chemokine SDF1 [8,9]
that plays a critical role in both embryonic B lymphopoiesis
and organogenesis [10]. A chemoattractant for the pluripotent
hematopoietic CD34+ cells [11] and a growth factor for pre-
and pro-B murine lymphocytes in vitro [12], SDF1 is also
known to promote the arrest on endothelium of lymphocytes
rolling under £ow conditions [13]. Moreover, SDF1 prevents
HIV entry in host cells by both occupying [8,9] and promoting
endocytosis of CXCR4 [14]. Nowadays, CXCR4 seems to be
the only receptor capable of binding SDF1 selectively and
permit cell signaling by this chemokine [8,15]. CXCR4 is ex-
pressed constitutively in a large number of human tissues and
transformed cell lines [15]. Moreover, CXCR4 transcripts are
very abundant in leukocytes [15].
To investigate the mechanisms controlling both the constit-
utive and induced expression of CXCR4 receptors, we have
isolated and characterized the promoter region and deter-
mined the genomic structure of the human gene. The
CXCR4 gene contains two exons separated by an intronic
sequence. A 2.6 kb 5P-£anking region located upstream the
CXCR4 open reading frame contains a TATA box and the
transcription start site characteristic of a functional promoter.
This region also contains putative consensus binding sequen-
ces for di¡erent transcription factors, some of them associated
with hemopoiesis and lymphocyte development.
2. Materials and methods
2.1. Cells
The epithelial-like cell line HeLa was propagated in DMEM me-
dium supplemented with 10% heat-inactivated fetal calf serum (FCS,
Gibco), L-Gln and antibiotics. J.jhan cells were derived from the T
lymphoblastoid cell line Jurkat and were grown in RPMI 1640 sup-
plemented with 10% FCS. Peripheral blood mononuclear cells
(PBMC) were isolated by Ficoll gradient from healthy human donors.
2.2. DNA sequencing
Both DNA strands relative to the CXCR4 gene and the promoter
region were sequenced by the dideoxy-chain termination method using
the New England Biolabs cycle sequencing Kit and an automated
sequencer ABI (Perkin Elmer). All sequencings were done in dupli-
cate.
2.3. Library screening
A human BAC library from Research Genetics, Inc (2130 Memorial
Parkway SW, Huntsville, AL 35801, USA) was screened according to
the manufacturer’s instructions by speci¢c PCR for the CXCR4 gene.
The primers used were CXCR45459: 5P-CCGAGGAAATGGGCT-
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CAGGGGA-3P and CXCR45462: 5P-CATTGGGGTAGAAGCG-
GTCACA-3P. The PCR mixtures contained 5 Wl of DNA from the
BAC library pool, 1 Wl of each primer at a concentration of 500 ng/Wl,
200 mM dNTPs, 1 mM of MgCl2, 0.2 units of Taq DNA polymerase
(Pharmacia), 5 Wl of DMSO and water to 100 Wl. Ampli¢cation was
conducted for 30 cycles at 93‡C 1 min, 62‡C 2 min, 72‡C 2.30 min,
followed by a ¢nal elongation step at 72‡C for 15 min. The PCR
products were visualized on a 2% agarose gel stained with ethidium
bromide. This procedure led to the identi¢cation of a BAC clone
(24D3) that contained the entire CXCR4 gene and adjacent sequen-
ces. The identi¢cation of a putative TATA box and consensus binding
sites for transcription factors were performed using the program
TESS (Transcription Element Search Software) (http://agave.hum-
gen.upenn.edu/tess/index.html). Only sequences showing total homol-
ogy with the canonical consensus sequence for transcription factors
were considered.
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Fig. 1. Sequence of the CXCR4 gene and promoter region. The consensus TATA box sequence and putative transcription factor consensus
sites are indicated above the sequence. The two coding regions are represented in bold capital letters and the 5P UTR in italic capital letters. A
schematic representation of the CXCR4 gene structure with reference to the principal hallmarks of the sequence and the restriction pattern is
represented at the botton of the ¢gure.
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2.4. Southern blotting
Ten micrograms of BAC 24D3 DNA were digested with EcoRI,
BamHI, XbaI, HindIII, SstI, PstI, XhoI, KpnI and SpeI, run on a
0.8% agarose gel, and blotted onto a nitrocellulose membrane. A
radioactive probe was synthesized by PCR ampli¢cation of a
CXCR4 cDNA plasmid in the presence of 0.5 mM of K32P-dATP
and the previously described primers. This probe was hybridized to
the nitrocellulose membrane. This procedure led to the identi¢cation
of 3.5 and 3.7 kb bands of BamHI digested BAC DNA that contained
the CXCR4 gene. These fragments were subcloned in pBluescript
SK þ (Stratagene) and sequenced. Further direct sequencing of the
BAC clone permitted the identi¢cation of additional 1.8 kb more
relative to the 5P end of the sequence characterized previously.
2.5. Primer extension
After RNA extraction from HeLa cells using the PolyATtract
mRNA isolation system (Promega), CXCR4 cDNA synthesis was
performed with 100 ng of Q32P-ATP end-labeled primer complemen-
tary to the coding strand of the 3P end of exon 1 (5P-GGTTCTCCA-
GATGCGGTGGCTACTGGAGCACTCAGGCCCT-3P). The same
primer was used as sequencing primer of the genomic DNA and
both products were electrophoresed in 6% polyacrylamide gel.
2.6. Construction of reporter plasmids
The larger promoter region of CXCR4 and the deletion variants
were cloned from the genomic DNA by PCR into the eukaryotic
expression plasmid pGEM luc (Promega). To reduce the likelihood
of PCR generated mutations, all reactions were performed with Pfu
DNA polymerase (Stratagene) and the ampli¢ed material was veri¢ed
by sequencing. To facilitate subcloning in the expression plasmid, the
primers used included the HindIII and the BamHI site at the 5P and
3P ends, respectively, for the construction smaller than 1 kb and
the BamHI and NotI for constructing the 2.6 kb promoter frag-
ment. All PCR ampli¢cations were carried out using the antisense
primer 5P-TCGAGGATCCCCAACAAACTGAAGTTTCTG which
encompasses the transcription start site (+1). Speci¢c sense primers
for ampli¢cation of the di¡erent promoter regions were: 32643/+1,
5P-GATCGCGGCCGCACTTAATGTTTCATAAGTATTTC-3P ;
3888/+1, 5P-TCGAAAGCTTGGATCCCCACGCCTAGAAC-3P ;
3417/+1, 5P-TCGAAAGCTTATTGCCGCCTACT-3P ; 3110/+1, T-
CGAAAGCTTCCTCGCGTCTGCCC-3P ; 363/+1, 5P-TGGAAAG-
CTTAGCGGCGCATGCGC-3P ; 348/+1, TCGAAAGCTTGCGCT-
CGGAGCGTGTTTTTA-3P.
2.7. Transfection and luciferase assay
Transfections of cells were performed by electroporation. The con-
ditions used were: 320 V and 1500 WF for PBMC; 260 V and 1500 WF
for J.jhan; and 200 V, 900 WF for HeLa. Twenty-four hours upon
transfection cells were stimulated for 18 h with the di¡erent stimuli.
Phorbol myristate acetate (PMA, Sigma) was used at 20 ng/ml. Ion-
omycine (Sigma) and Phytohemagglutinin (PHA, Welcome) were used
at 250 ng/ml and 1 Wg/ml, respectively. Final concentrations of re-
combinant TNF, IL2 and synthetic SDF1K were 5 ng/ml, 30 IU/ml
and 100 nM, respectively. Stimulation with either anti-CD3 or anti-
CD3+anti-CD28 antibodies were performed as described previously
[16]. The luciferase activity generated in cell cultures was assessed
using a commercially available kit (Boehringer Mannheim) according
to the manufacturer’s instructions. Results are expressed as relative
light units (RLU) per milligram of protein after subtracting the back-
ground signal (lysate from non-transfected cells).
3. Results and discussion
A fragment of 8724 base pairs (bp) containing the totality
of the CXCR4 coding region and 2.6 and 2.3 kb £anking
sequences relative to 5P and 3P, respectively, was isolated
from a human genomic BAC library (the accession number
in EMBL database is AJ224869). The analysis of the sequence
revealed that the CXCR4 open reading frame is encoded as
two exons separated by a 2.1 kb of intronic sequence. The ¢rst
exon carries the sequence corresponding to the ¢ve ¢rst
CXCR4 amino acids and a 5P UTR region. The second
exon codes for the last 247 amino acids and a 3P UTR se-
quence. The entire nucleotidic sequence corresponding to the
CXCR4 ORF and £anking regions, along with a schematic
representation of the CXCR4 gene, is shown in Fig. 1. Six
base pairs downstream last codon of the ¢rst exon, we noted
the presence of an alternative canonical splice donor site
(GT). This is reminiscent of an alternative splice donor site
found in the mouse CXCR4 gene which permits expression of
two di¡erent transcripts [17,18]. In contrast with these results,
we failed to prove that the hypothetical, alternative splicing
donor site found in human CXCR4 gene we identi¢ed was
e⁄ciently used to generate two mRNA species in normal
(PBMC) and transformed (J.jhan, HeLa) human cells.
To identify the promoter region boundaries, we performed
a computer-assisted analysis of the sequence data. A consen-
sus TATA box sequence was recognized 30 bp 5P upstream
transcription start site (Fig. 2), suggesting that this region was
the promoter of the CXCR4 gene. The CXCR4 promoter
region herein described is identical to that recently described
by Morihuchi et al. [19] and contains an additional and pre-
viously unidenti¢ed 5P regulatory region of 1.4 kb. The
CXCR4 promoter region carries di¡erent consensus binding
sites for transcriptional factors. Some of these factors are
supposed to be associated with hemopoiesis or lymphocyte
maturation (MAZ, C-ets2, PU.1, PEA3, Lyf1) [20^23]. Seven
putative consensus binding sites for the ubiquitous SP1 se-
quence were also identi¢ed.
To functionally characterize the promoter region of
CXCR4, a series of 5P truncations of this region were sub-
cloned into a plasmid driving the expression of a luciferase
gene. Upon transfection into di¡erent human cell types, both
the constitutive and the induced expression of luciferase was
measured in cytoplasmic lysates obtained from disrupted cells.
Spontaneous transcriptional activity from the CXCR4 was
observed from the promoter in the three cell types, J.jhan,
HeLa (Fig. 3) and PBMC (Fig. 4B). In both HeLa and
J.jhan cells, the maximal transcription activity corresponded
to the construct carrying the longest region (32643/+1) of the
promoter. Truncation of sequences progressing from the 5P
end reduced basal activity of the promoter in all three cell
types. The e¡ect was more striking in HeLa cells where re-
moval of 5P sequences between 32643 and 3888 led to a ¢ve-
fold reduction of promoter activity (Fig. 3). The region span-
ning from 348 to +1 retained a signi¢cant level of transcrip-
tional activity, roughly comparable to that displayed by con-
structs encoding upstream sequences up to position 3417.
This ¢nding suggests that sequences from 348 to +1 contain
the proximal element accounting for the basal activity of the
promoter. We could not con¢rm that removal of the NRF1
consensus site for the transcription factor (373/362) which
has been described [19] as controlling the activity of the
CXCR4 minimal promoter, a¡ected signi¢catively the basal
activity of the promoter. Di¡erences in the type of cells used
in this study might account for the divergent results.
Our ¢ndings indicate that the 1.4 kb region that we have
identi¢ed and is located upstream the previously characterized
promoter region [19], also contains regulatory elements in-
volved in the control of CXCR4 constitutive transcription
activity. The participation of distal regions in the control of
the basal activity was more marked in epithelial cells as com-
pared to lymphoid cells, thus suggesting some degree of tissue
speci¢city in the regulation of the CXCR4 promoter.
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The capacity of the CXCR4 promoter to undergo trans-
activation upon stimulation by cell activation signals was as-
sessed using the regulatory sequences between positions 3888
and +1. Among the di¡erent stimuli used, only combined
addition of PMA and ionomycin proved to be an e⁄cient
signal to enhance transcription activity from the promoter
in the three cell types tested (Fig. 4A and B). Thus, the ca-
pacity of di¡erent regions of the promoter to be induced and
transactivated by cell activation signals was investigated by
using simultaneous addition of PMA and ionomycin. We
show that the promoter regions responding to cell activation
di¡er in HeLa and J.jhan cells (Fig. 5A and B). Indeed, in
HeLa cells promoter transactivation requires the presence of
the more distal regions (upstream position 3417). In contrast,
in lymphoblastoid J.jhan cells proximal promoter elements
retained signi¢cant reactivity to activation of cell signals.
Thus, similar to the constitutive expression of the CXCR4
promoter, induced transcription upon cell activation may
have some degree of tissue speci¢city that would depend on
selective protein/DNA interactions.
The capacity of stimuli mimicking physiologic activation of
T lymphocytes to transactivate the CXCR4 promoter, was
investigated. Upon transfection with the (888/+1)-driven luci-
ferase construct, J.jhan or HeLa cells (Fig. 4A) were treated
with either TNF or SDF1K. The transcription activity of the
promoter was not modi¢ed by either stimuli despite they in-
duced e⁄ciently cells as indicated by IUBK degradation (TNF)
or CXCR4 endocytosis and calcium mobilization (SDF1K) in
both cell types (data not shown). Using PBMC (Fig. 4B) we
also investigated the capacity of T lymphocyte mitogenic sig-
nals or IL2 to enhance transcriptional activity from the
CXCR4 promoter. The constitutive activity of the promoter
was not modi¢ed signi¢cantly by stimulation of PBMC with
anti-CD3, anti-CD3+anti-CD28 antibodies or incubation with
IL2, although these stimuli induced CD25 expression and cell
proliferation (data not shown).
The constitutive expressions of the CXCR4 promoter in
di¡erent cell types are in keeping with the constitutive expres-
sion of CXCR4 gene observed in human tissues [15]. CXCR4
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Fig. 3. Basal activity of the 2643 bp CXCR4 promoter and di¡erent deletions in transfected HeLa and J.jhan cells. Values on top of columns
are relative to these of construct (32643/+1) which we set arbitrary as 1.
Fig. 2. Identi¢cation of transcription start site of the CXCR4
mRNA by primer extension in Hela cells. The ¢rst line represents
the major CXCR4 cDNA extension product, electrophoresed in the
same gel as the sequencing reaction of the genomic DNA right four
lines.
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transcripts are expressed in a large diversity of tissues and
transformed cell lines [14,15]. The expression of CXCR4 is
also constitutive in cells of hematopoietic origin. Indeed,
CXCR4 is expressed in most human resting T lymphocytes
isolated from blood although the percentage of positive cells
shows some degree of variability among blood donors [14,24].
CXCR4 is also expressed in most of 60% freshly isolated,
human blood monocytes [24]. Interestingly in Langerhans
and endothelial cells, constitutive expression of CXCR4 is
detected and the protein accumulates in the cytoplasm
[25,26]. Langerhans cells when kept in culture for some hours
after isolation show CXCR4 at the cell membrane thus sug-
gesting that the lack of cell surface expression could be related
to microenvironmental in£uences [25].
However, we have not found cell signals induced by either
cytokines or growth factors, or mediated through membrane
receptors involved in speci¢c T lymphocyte activation, capa-
ble to up-regulate the constitutive transcription activity of the
CXCR4 promoter. Our data diverge from those of Moriuchi
et al. [19] who found a discrete enhancement of CXCR4 pro-
moter transcription activity in PBMC activated by IL2 or via
CD3. Di¡erences in the status of cell activation and di¡er-
entiation might explain these divergent data. Indeed, while the
experiments described by Moriuchi et al. were performed in
blast T lymphocytes expanded with IL2, we transfected and
induced resting PBMC. In keeping with the results published
by Moriuchi et al., the enhancement of CXCR4 expression at
the cell membrane in PHA-activated human T lymphocytes
has been reported previously [6]. Nevertheless and in sharp
contrast with these data, evidence supporting down-regulation
of CXCR4 expression in PHA-stimulated T lymphocytes has
been provided by Loetscher et al. [15]. Findings obtained in
our laboratory con¢rmed Loetscher et al.’s observations and
show that PHA activation induces a rapid and sustained re-
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Fig. 4. Induction of the 3888/+1 promoter region with di¡erent stimuli in HeLa and J.jhan cells (A) and healthy donor PBMC (B). The fold
increases with respect to the promoter without stimulus are indicated on top of each column.
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duction in the amount of CXCR4 transcripts and impair
CXCR4 cell membrane expression in PBMC (Caruz and Al-
cami, unpublished results). This observation could re£ect ei-
ther induction of a transcription inhibition mechanism or
more likely a reduced stability of the CXCR4 messenger.
Down-regulation of chemokine receptor after cell activation
is not without precedent, and has been described previously
for the chemokine receptors CCR1 and CCR2. Indeed, mito-
genic activation of fully responsive lymphocytes dramatically
reduced the amount of transcripts for both receptors and lead
to the loss of responsiveness to RANTES and MCP-1, respec-
tively [4]. Moreover, it has been shown recently that IFNQ, a
cytokine secreted by PBMC lymphocytes in response to mito-
genic stimuli [27], profoundly down-regulates CXCR4 mRNA
expression in endothelial cells, a monocytoid cell line and
PBMC [28,29]. The apparently divergent ¢ndings described
above should be resolved by a more detailed analysis of the
physiologic signals regulating the expression of the CXCR4
gene both at pre- and post-transcriptional phases in di¡erent
cell types.
Taking into account the important role played by SDF1 in
embryo development and immunological functions, on one
hand, and given that CXCR4 is the only SDF1 receptor iden-
ti¢ed so far, the analysis of mechanisms regulating expression
of the CXCR4 gene appears like a topic of outstanding inter-
est for future work.
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Fig. 5. Induction of CXCR4 promoter constructions by PMA and ionomycin compared with the basal level in Hela (A) or J.jhan (B) cells.
The fold increases with respect to the control without stimulus are represented over each column.
A. Caruz et al./FEBS Letters 426 (1998) 271^278 277
References
[1] Baggiolini, M., Dewald, B. and Moser, B. (1994) Adv. Immunol.
55, 97^179.
[2] Murphy, P.M. (1996) Cytokine Growth Fact. Rev. 7, 47^64.
[3] Rollins, B.J. (1997) Blood 90, 909^928.
[4] Loetscher, P., Seitz, M., Baggiolini, M. and Moser, B. (1996)
J. Exp. Med. 184, 569^577.
[5] Bleul, C.C., Wu, L.J., Hoxie, J.A., Springer, T.A. and Mackay,
C.R. (1997) Proc. Natl. Acad. Sci. USA 94, 1925^1930.
[6] Carroll, R. et al. (1997) Science 276, 273^276.
[7] Feng, Y., Broder, C.C., Kennedy, P.E. and Berger, E.A. (1996)
Science 272, 872^877.
[8] Oberlin, E. et al. (1996) Nature 382, 833^835.
[9] Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clarklewis, I.,
Sodroski, J. and Springer, T.A. (1996) Nature 382, 829^833.
[10] Nagasawa, T. et al. (1996) Nature 382, 635^638.
[11] Aiuti, A., Webb, I.J., Bleul, C., Springer, T. and Gutierrez-Ra-
mos, J.C. (1997) J. Exp. Med. 185, 111^120.
[12] Nagasawa, T. et al. (1996) Proc. Natl. Acad. Sci. USA 93, 14726^
14729.
[13] Campbell, J., Hedrick, J., Zlotnik, A., Siani, M.A., Thompson,
D.A. and Butcher, E.C. (1998) Science 279, 381^384.
[14] Amara, A. et al. (1997) J. Exp. Med. 186, 139^146.
[15] Loetscher, M., Geiser, T., O’Reilly, T., Zwahlen, R., Baggiolini,
M. and Moser, B. (1994) J. Biol. Chem. 9, 232^237.
[16] Alcami, J. et al. (1995) EMBO J. 114, 1552^1560.
[17] Moepps, B., Frodl, R., Rodewald, H.R., Baggiolini, M. and
Gierschik, P. (1997) Eur. J. Immunol. 27, 2102^2112.
[18] Heesen, M., Berman, M.A., Hopken, U.E., Gerard, N.P. and
Dorf, M.E. (1997) J. Immunol. 158, 3561^3564.
[19] Moriuchi, H., Moriuchi, M., Combadiere, C., Murphy, P.M. and
Fauci, A.S. (1996) Proc. Natl. Acad. Sci. USA 93, 15341^15345.
[20] Omori, S.A. and Wall, R. (1993) Proc. Natl. Acad. Sci. USA 90,
11723^11727.
[21] Leung, E. et al. (1997) Immunogenetics 46, 111^119.
[22] Wasylyk, B., S L, H. and Giovane, A. (1993) Eur. J. Biochem.
211, 7^18.
[23] Bossone, S.A., Asselin, C., Patel, A.J. and Marcu, K.B. (1992)
Proc. Natl. Acad. Sci. USA 89, 7452^7456.
[24] Hori, T., Sakaida, H., Sato, A., Nakajima, T., Shida, H., Yoshie,
O. and Uchiyama, T. (1998) J. Immunol. 160, 180^188.
[25] Zaitseva, M., Blauvelt, A., Lee, S., Lapham, C.K., Klaus-Kav-
tun, V., Mostowski, H., Manischewitz, J. and Golding, H. (1997)
Nature Med. 3, 1369^1375.
[26] Volin, M.V., Joseph, L., Shockley, M.S. and Davies, P.F. (1998)
Biochem. Biophys. Res. Commun. 242, 46^53.
[27] Farrar, M.A. and Schreibe, R.D. (1993) Annu. Rev. Immunol.
11, 571^611.
[28] Gupta, S.K., Lysko, P.G., Pillarisetti, K., Ohlstein, E. and Sta-
del, J.M. (1998) J. Biol. Chem. 273, 4282^4287.
[29] Shirazi, Y. and Pitha, P.M. (1998) J. Hum. Virol. 1, 69^76.
FEBS 20126 17-4-98
A. Caruz et al./FEBS Letters 426 (1998) 271^278278
